Evidence map›Paper›PMID 38532546›Full record

SynthesisThoracic cancer2024

Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis.

Yao Zhang, Huiting Li, Bo Yu, Si Sun, Zhihuang Hu, Xianghua Wu, Yang Zhang, Bin Li, Yawei Zhang, Jiaqing Xiang and 2 more

Abstract readReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Thoracic cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yao ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0003-1174-7049
Huiting LiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Bo YuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Si SunDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhihuang HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0002-6547-3832
Xianghua WuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yang ZhangDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Bin LiDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Yawei ZhangDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Jiaqing XiangDepartment of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
Jialei WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0001-9977-2219
Hui YuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant chemoimmunotherapy (NCIT) for locally advanced esophageal squamous cell carcinoma (ESCC) is supported by increasing data, but the sample size is limited, and the findings are not completely consistent. We conducted a real-world study and a meta-analysis to evaluate the efficacy and safety of NCIT in locally advanced ESCC.

methodsWe retrospectively assessed the outcomes of patients with locally advanced ESCC who completed NICT and subsequent esophagectomy at our hospital between January 2019 and December 2022, including pathological complete response (pCR) rate, major pathological response (MPR) rate, 1-, 2-, and 3-year overall survival (OS) rates, disease control rate (DCR), objective response rate (ORR), 1-year recurrence rate, R0 resection rate and adverse events. Moreover, a meta-analysis of 27 published literatures was also conducted for comparison.

resultsIn the analysis, 128 patients were studied, with 25% achieving pCR, 46.1% MPR, and 99.2% R0 resection. The 1-, 2-, and 3-year OS rates were 91.41% (95% CI: 85.15%-95.63%), 75.00% (95% CI: 66.58%-82.23%) and 64.84% (95% CI: 55.91%-73.07%).ORR and DCR were 31.2% (95% CI: 23.31-39.99) and 64.1% (95% CI: 55.15%-72.38%), and the 1-year recurrence rate was 26.7% (95% CI: 22.5%-38.1%). Treatment-related events occurred in 96.1% but were acceptable. In a meta-analysis of 27 studies with 1734 patients, pooled rates for pCR, MPR, ORR, DCR, and R0 resection were 29%, 52%, 71%, 97%, and 98%, respectively, with a 1-year recurrence rate of 12%.

conclusionNCIT is safe and provides potential survival benefits for patients with locally advanced ESCC. However, randomized phase 3 trial data is still needed.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaImmunotherapyNeoadjuvant TherapyAdultAgedFemaleHumansMaleMiddle AgedRetrospective Studiesefficacylocally advanced esophageal squamous cell carcinomaneoadjuvant chemoimmunotherapysafetysurvival outcomes

Identifiers

PMID38532546
PMCPMC11062853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.